![conference banner](/images/conference-banner.jpeg)
Abstract
A series of 2´-hydroxy-4´,6´-diisoprenyloxychalcone derivatives were synthesized and evaluated for inhibitory activities against CDC25B and PTP1B. The results displayed the most of them showed inhibitory activities against CDC25B (IC50=1.19–14.20 µg/mL) and PTP1B (IC50= 1.26–8.44µg /mL), respectively. Moreover, compound 2h displayed the most CDC25B and PTP1B inhibitory activity in vitro with IC50 values of 1.19 and 1.26 µg/mL, respectively, compared with reference drugs Na3VO4(IC50=1.09 µg/mL) and oleanolic acid (IC50=1.01 µg/mL). The results of selectivity experiments showed that the target compounds were selective inhibitors against CDC25B and PTP1B. Enzyme kinetic experiments demonstrated that compound 2h was a specific inhibitor with the typical characteristics of a mixed inhibitor.
Keywords: 2´-Hydroxy-4´, 6´-diprenyloxychalcone, synthesis, CDC25B, PTP1B, phosphatase inhibitors, enzyme kinetic.
Letters in Drug Design & Discovery
Title:Synthesis and Biological Evaluation of 2´-Hydroxy-4´,6´-Diprenyloxychal-Cone Derivatives as Potent CDC25B and PTP1B Inhibitors
Volume: 12 Issue: 10
Author(s): Dong-Hai Zhao, JIan Zhang, Lei Zhang, Da-Peng Li, Zhou Peng and Li-Ping Guan
Affiliation:
Keywords: 2´-Hydroxy-4´, 6´-diprenyloxychalcone, synthesis, CDC25B, PTP1B, phosphatase inhibitors, enzyme kinetic.
Abstract: A series of 2´-hydroxy-4´,6´-diisoprenyloxychalcone derivatives were synthesized and evaluated for inhibitory activities against CDC25B and PTP1B. The results displayed the most of them showed inhibitory activities against CDC25B (IC50=1.19–14.20 µg/mL) and PTP1B (IC50= 1.26–8.44µg /mL), respectively. Moreover, compound 2h displayed the most CDC25B and PTP1B inhibitory activity in vitro with IC50 values of 1.19 and 1.26 µg/mL, respectively, compared with reference drugs Na3VO4(IC50=1.09 µg/mL) and oleanolic acid (IC50=1.01 µg/mL). The results of selectivity experiments showed that the target compounds were selective inhibitors against CDC25B and PTP1B. Enzyme kinetic experiments demonstrated that compound 2h was a specific inhibitor with the typical characteristics of a mixed inhibitor.
Export Options
About this article
Cite this article as:
Zhao Dong-Hai, Zhang JIan, Zhang Lei, Li Da-Peng, Peng Zhou and Guan Li-Ping, Synthesis and Biological Evaluation of 2´-Hydroxy-4´,6´-Diprenyloxychal-Cone Derivatives as Potent CDC25B and PTP1B Inhibitors, Letters in Drug Design & Discovery 2015; 12 (10) . https://dx.doi.org/10.2174/1570180812666150723002629
DOI https://dx.doi.org/10.2174/1570180812666150723002629 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
Call for Papers in Thematic Issues
Navigating the Frontier: Probiotics' Promising Path in Combatting Viral Respiratory Infections, Spotlight on Coronaviridae.
Probiotics, well-known for their role in gut health, show promise in preventing and managing respiratory virus infections, particularly in children and at-risk populations. However, the profound influence of novel pathogenic viral RTIs such as coronaviruses has reshaped perspectives on the potential of probiotics. Despite their potential, significant gaps remain in ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dendrimers As Vectors for Genetic Material Delivery to the Nervous System
Current Medicinal Chemistry Recent Advances in Receptor-Targeted Fluorescent Probes for In Vivo Cancer Imaging
Current Medicinal Chemistry Immunoregulatory and Effector Activities of Nitric Oxide and Reactive Nitrogen Species in Cancer
Current Medicinal Chemistry Genomics and Pharmacogenomics of Brain Disorders
Current Pharmaceutical Biotechnology Solid Matrix Based Lipidic Nanoparticles in Oral Cancer Chemotherapy: Applications and Pharmacokinetics
Current Drug Metabolism Cancer Stem Cells in Prostate Cancer Chemoresistance
Current Cancer Drug Targets Novel Agents in the Management of Lung Cancer
Current Medicinal Chemistry Engineered Liposomes for Drug Delivery and Biomedical Imaging
Recent Patents on Nanomedicine Cancer Stem Cells in Carcinogenesis and Potential Role in Pancreatic Cancer
Current Stem Cell Research & Therapy The Endothelin Axis as Therapeutic Target in Human Malignancies: Present and Future
Current Pharmaceutical Design MicroRNA-490-5P Targets CCND1 to Suppress Cellular Proliferation in Glioma Cells and Tissue Through Cell Cycle Arrest
Current Neurovascular Research Clonetics
Current Drug Metabolism The Proteolytic Activation of Angiogenic and Lymphangiogenic Growth Factors in Cancer – Its Potential Relevance for Therapeutics and Diagnostics
Current Medicinal Chemistry The Development of PDGF Receptor Inhibitors for the Treatment of Glioma: A Review
Letters in Drug Design & Discovery Molecular Dynamics of Protein Kinase-Inhibitor Complexes: A Valid Structural Information
Current Pharmaceutical Design Subject Index To Volume 6
Central Nervous System Agents in Medicinal Chemistry The Role of Mammalian Target of Rapamycin (mTOR) Inhibitors in the Treatment of Solid Tumors
Current Cancer Therapy Reviews Phosphonate Analogues of 1α, 25 Dihydroxyvitamin D<sub>3</sub> are Promising Candidates for Antitumoural Therapies
Current Topics in Medicinal Chemistry Therapeutic Exploitation of Apoptosis and Autophagy for Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs in Glioblastoma: Role in Pathogenesis and Opportunities for Targeted Therapies
CNS & Neurological Disorders - Drug Targets